Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of its 1,000th batch of sterile injectable drug product, marking a major milestone for the Scotland-based CDMO.

Founded in 2011, Symbiosis has grown from a local startup into an international manufacturer supporting both clinical development and commercial supply. Its expertise spans monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors, small molecules, and advanced therapy medicinal products (ATMPs).

The company notably supported the development of the Oxford University/AstraZeneca COVID-19 vaccine, manufacturing close to one million clinical doses at its Stirling facility during the pandemic.

Symbiosis now provides manufacturing support across phase 1–3 trials and commercial programs globally. The company reports a consistent record of successful GMP inspections by the US FDA, UK MHRA, and other regulators.

“This milestone reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster,” said Colin MacKay, CEO of Symbiosis.

The company has recently expanded its capabilities with a new automated commercial-scale manufacturing facility in Stirling and was named a 2025 King’s Award for Enterprise winner in International Trade.